Trial ID # | NCT01633970 |
Phase | Ib |
Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
Drug Name | Atezolizumab |
Alternate Drug Names | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A , MPDL3280A, RG7446 |
Drugs in Trial | Atezolizumab, Bevacizumab |
Eligible Participant | Platinum resistant or refractory ovarian cancer |
Patients Enrolled | 20 |
Therapy Setting | Recurrence |
Study Design | Open-Label, Non-randomized |
Endpoints | ORR, DCR, PFS, OS, evaluated per RECIST |
Efficacy | ORR: 15% (3PR, n=20) |
Clinically Significant Adverse Events | Serious AE: none |
Conclusion | Atezolizumab+bevacizumab induces durable responses and/or disease stabilization in some patients with platinum-resistant ovarian cancer; the safety profiles are consistent with those of each agent |
Reference | Moroney JW et al. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res (2020) 26(21):5631-5637 |